• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Med (N Y) . Evidence for SARS-CoV-2 Delta and Omicron co-infections and recombination

tetano

Editor, Senior Moderator
Med (N Y)


. 2022 Oct 20;S2666-6340(22)00449-4.
doi: 10.1016/j.medj.2022.10.002. Online ahead of print.
Evidence for SARS-CoV-2 Delta and Omicron co-infections and recombination


Alexandre Bolze[SUP] 1 [/SUP], Tracy Basler[SUP] 1 [/SUP], Simon White[SUP] 1 [/SUP], Andrew Dei Rossi[SUP] 1 [/SUP], Dana Wyman[SUP] 1 [/SUP], Hang Dai[SUP] 1 [/SUP], Pavitra Roychoudhury[SUP] 2 [/SUP], Alexander L Greninger[SUP] 2 [/SUP], Kathleen Hayashibara[SUP] 3 [/SUP], Mark Beatty[SUP] 4 [/SUP], Seema Shah[SUP] 4 [/SUP], Sarah Stous[SUP] 4 [/SUP], John T McCrone[SUP] 1 [/SUP], Eric Kil[SUP] 1 [/SUP], Tyler Cassens[SUP] 1 [/SUP], Kevin Tsan[SUP] 1 [/SUP], Jason Nguyen[SUP] 1 [/SUP], Jimmy Ramirez[SUP] 1 [/SUP], Scotty Carter[SUP] 1 [/SUP], Elizabeth T Cirulli[SUP] 1 [/SUP], Kelly Schiabor Barrett[SUP] 1 [/SUP], Nicole L Washington[SUP] 1 [/SUP], Pedro Belda-Ferre[SUP] 1 [/SUP], Sharoni Jacobs[SUP] 1 [/SUP], Efren Sandoval[SUP] 1 [/SUP], David Becker[SUP] 1 [/SUP], James T Lu[SUP] 1 [/SUP], Magnus Isaksson[SUP] 1 [/SUP], William Lee[SUP] 1 [/SUP], Shishi Luo[SUP] 5 [/SUP]



Affiliations
Free PMC article

Abstract

Background: Between November 2021 and February 2022, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta and Omicron variants co-circulated in the United States, allowing for co-infections and possible recombination events.
Methods: We sequenced 29,719 positive samples during this period and analyzed the presence and fraction of reads supporting mutations specific to either the Delta or Omicron variant.
Findings: We identified 18 co-infections, one of which displayed evidence of a low Delta-Omicron recombinant viral population. We also identified two independent cases of infection by a Delta-Omicron recombinant virus, where 100% of the viral RNA came from one clonal recombinant. In the three cases, the 5' end of the viral genome was from the Delta genome and the 3' end from Omicron, including the majority of the spike protein gene, though the breakpoints were different.
Conclusions: Delta-Omicron recombinant viruses were rare, and there is currently no evidence that Delta-Omicron recombinant viruses are more transmissible between hosts compared with the circulating Omicron lineages.
Funding: This research was supported by the NIH RADx initiative and by the Centers for Disease Control Contract 75D30121C12730 (Helix).

Keywords: BA.1; Delta; Omicron; RNA virus; SARS-CoV-2; Translation to patients; alternative allele fraction; breakpoint; co-infection; recombination; sequencing.
 
Back
Top Bottom